首页> 外文期刊>Molecular medicine reports >Reversing effect and mechanism of soluble resistance-related calcium-binding protein on multidrug resistance in human lung cancer A549/DDP cells
【24h】

Reversing effect and mechanism of soluble resistance-related calcium-binding protein on multidrug resistance in human lung cancer A549/DDP cells

机译:可溶性耐药相关钙结合蛋白对人肺癌A549 / DDP细胞多药耐药的逆转作用及其机制

获取原文
获取原文并翻译 | 示例
           

摘要

Lung cancer is the primary malignancy of the lung and is the leading cause of cancer-associated mortality in China. Multidrug resistance (MDR) is an essential aspect of lung cancer treatment failure and a popular topic of investigation in tumor studies. Previous studies have demonstrated that soluble resistance-related calcium-binding protein (Sorcin) is involved in the MDR of various types of human tumor, and that silencing Sorcin was able to reverse the MDR of several types of cultured human cancer cells. However, the effect and potential mechanism underlying the ability of Sorcin to reverse MDR in human lung cancer remains to be fully elucidated. The present study examined the role of Sorcin in the reversal of MDR in human lung cancer A549/DDP cells. The effects included increased drug sensitivity to cisplatin, apoptotic rate, cell cycle arrest in the G2/M phase and intracellular accumulation of rhodamine-123, and decreased expression of multidrug resistance gene 1, lung resistance protein, multidrug resistance-associated protein, glutathione S-transferase pi, ATP-binding cassette transporter A2 (ABCA2), ABCA5, B-cell lymphoma 2 and P-glycoprotein, and the depletion of glutathione in Sorcin-silenced A549/DDP cells. The present study also revealed that there was a downregulation of p-Akt and phosphorylated extracellular signal-regulated kinase (p-ERK), and a decreased transcriptional activation of nuclear factor kappa B, signal transducer and activator of transcription (STAT)3, STAT5 and nuclear factor of activated T-cells following silencing of Sorcin. The results indicated that Sorcin may be used as a potential therapeutic target for MDR through inhibiting the Akt and ERK pathways in human lung cancer.
机译:肺癌是肺部的主要恶性肿瘤,是中国癌症相关死亡率的主要原因。多药耐药性(MDR)是肺癌治疗失败的重要方面,也是肿瘤研究中一个受欢迎的研究主题。先前的研究表明,可溶性抗性相关的钙结合蛋白(Sorcin)参与了各种类型人类肿瘤的MDR,而沉默Sorcin能够逆转几种培养的人类癌细胞的MDR。然而,尚不清楚Sorcin逆转人类肺癌MDR能力的作用和潜在机制。本研究检查了Sorcin在人类肺癌A549 / DDP细胞MDR逆转中的作用。这些作用包括增加对顺铂的药物敏感性,凋亡率,G2 / M期细胞周期停滞和若丹明-123的细胞内积累,以及降低多药耐药基因1,肺耐药蛋白,多药耐药相关蛋白,谷胱甘肽S的表达。 -转移酶pi,ATP结合盒转运蛋白A2(ABCA2),ABCA5,B细胞淋巴瘤2和P-糖蛋白,以及在Sorcin沉默的A549 / DDP细胞中谷胱甘肽的消耗。本研究还表明,p-Akt和磷酸化的细胞外信号调节激酶(p-ERK)的表达下调,而核因子κB,信号转导子和转录激活子(STAT)3,STAT5的转录激活降低。 Sorcin沉默后激活的T细胞的核因子和核因子。结果表明,Sorcin可通过抑制人类肺癌中的Akt和ERK途径用作MDR的潜在治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号